Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.46 USD
+0.01 (1.28%)
Updated May 9, 2024 03:59 PM ET
After-Market: $0.46 0.00 (0.44%) 5:06 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Redhill Biopharma Ltd. [RDHL]
Reports for Purchase
Showing records 121 - 140 ( 228 total )
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
A Strong Start for Donnatal and EnteraGam; Clinical Updates in 3Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Crohn''s Interim Readout in Early August - Expect Continuation
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Positive Results From Bekinda Study; A Second Study May Be Necessary: Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Bekinda Phase 3 to Report in 2Q17; Looking to First Product Launches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Proprietary Survey of Emergency Department Physicians Provides Clarity on Bekinda; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Donnatal Launch and Bekinda Results Are the Highlights of 2Q17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Concordia Agreement Starts Off a Catalyst-rich 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S